Swiss National Bank Has $1.85 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Swiss National Bank increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 105.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,000 shares of the company’s stock after buying an additional 36,900 shares during the period. Swiss National Bank’s holdings in NewAmsterdam Pharma were worth $1,850,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Keybank National Association OH bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at about $257,000. Handelsbanken Fonder AB bought a new position in NewAmsterdam Pharma during the fourth quarter worth about $4,816,000. TimesSquare Capital Management LLC increased its position in NewAmsterdam Pharma by 250.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company’s stock worth $23,016,000 after buying an additional 640,329 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. Finally, abrdn plc lifted its position in shares of NewAmsterdam Pharma by 38.7% in the fourth quarter. abrdn plc now owns 179,060 shares of the company’s stock valued at $4,602,000 after buying an additional 50,000 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $21.76 on Friday. The firm has a market cap of $2.39 billion, a PE ratio of -8.37 and a beta of -0.04. The stock’s fifty day moving average price is $21.66 and its two-hundred day moving average price is $21.20. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at approximately $305,550. This represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper purchased 1,135 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the acquisition, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 19.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on NAMS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Scotiabank raised their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Finally, Needham & Company LLC lowered their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.